UBS Downgrades Salix Pharmaceuticals To Neutral By: Benzinga via Benzinga February 24, 2015 at 08:16 AM EST Analysts at UBS downgraded Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) from Buy to Neutral. The price target for Salix Pharmaceuticals ... Read More >> Related Stocks: UBS Group Ag ADR